Literature DB >> 30057419

CD4+ T cell help in cancer immunology and immunotherapy.

Jannie Borst1, Tomasz Ahrends2, Nikolina Bąbała2, Cornelis J M Melief3, Wolfgang Kastenmüller4.   

Abstract

Cancer immunotherapy aims to promote the activity of cytotoxic T lymphocytes (CTLs) within a tumour, assist the priming of tumour-specific CTLs in lymphoid organs and establish efficient and durable antitumour immunity. During priming, help signals are relayed from CD4+ T cells to CD8+ T cells by specific dendritic cells to optimize the magnitude and quality of the CTL response. In this Review, we highlight the cellular dynamics and membrane receptors that mediate CD4+ T cell help and the molecular mechanisms of the enhanced antitumour activity of CTLs. We outline how deficient CD4+ T cell help reduces the response of CTLs and how maximizing CD4+ T cell help can improve outcomes in cancer immunotherapy strategies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30057419     DOI: 10.1038/s41577-018-0044-0

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  368 in total

1.  CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity.

Authors:  Austin P Huffman; Jeffrey H Lin; Samuel I Kim; Katelyn T Byrne; Robert H Vonderheide
Journal:  JCI Insight       Date:  2020-05-21

Review 2.  B cells, plasma cells and antibody repertoires in the tumour microenvironment.

Authors:  George V Sharonov; Ekaterina O Serebrovskaya; Diana V Yuzhakova; Olga V Britanova; Dmitriy M Chudakov
Journal:  Nat Rev Immunol       Date:  2020-01-27       Impact factor: 53.106

3.  IFN-Stimulated Gene 15 Is an Alarmin that Boosts the CTL Response via an Innate, NK Cell-Dependent Route.

Authors:  Victoria Iglesias-Guimarais; Tomasz Ahrends; Evert de Vries; Klaus-Peter Knobeloch; Andriy Volkov; Jannie Borst
Journal:  J Immunol       Date:  2020-03-13       Impact factor: 5.422

Review 4.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Authors:  Margaret L Axelrod; Rebecca S Cook; Douglas B Johnson; Justin M Balko
Journal:  Clin Cancer Res       Date:  2018-11-21       Impact factor: 12.531

Review 5.  CD8+ T cell states in human cancer: insights from single-cell analysis.

Authors:  Anne M van der Leun; Daniela S Thommen; Ton N Schumacher
Journal:  Nat Rev Cancer       Date:  2020-02-05       Impact factor: 60.716

6.  CD4+ T cell exhaustion leads to adoptive transfer therapy failure which can be prevented by immune checkpoint blockade.

Authors:  Jinfei Fu; Anze Yu; Xiang Xiao; Juyu Tang; Xiongbing Zu; Wenhao Chen; Bin He
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

7.  Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.

Authors:  Fumihiro Fujiki; Akihiro Tsuboi; Soyoko Morimoto; Naoya Hashimoto; Miki Inatome; Hiroko Nakajima; Jun Nakata; Sumiyuki Nishida; Kana Hasegawa; Naoki Hosen; Yoshihiro Oka; Yusuke Oji; Shinji Sogo; Haruo Sugiyama
Journal:  Cancer Immunol Immunother       Date:  2020-07-22       Impact factor: 6.968

Review 8.  Genomic correlates of response to immune checkpoint blockade.

Authors:  Tanya E Keenan; Kelly P Burke; Eliezer M Van Allen
Journal:  Nat Med       Date:  2019-03-06       Impact factor: 53.440

Review 9.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

10.  Proliferation-competent Tcf1+ CD8 T cells in dysfunctional populations are CD4 T cell help independent.

Authors:  Kristiyan Kanev; Ming Wu; Antar Drews; Patrick Roelli; Christine Wurmser; Madlaina von Hösslin; Dietmar Zehn
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.